How many glucagon-based drugs does Eli Lilly currently market?

It currently markets four glucagon-based drugs, including Mounjaro.

What clinical phase has the new drug reached?

The drug has successfully completed two Phase III trials, the final stage before regulatory submission.

When does Eli Lilly expect approval for the drug?

The company has not provided a specific timeline, but a regulatory submission is expected soon.

Eli Lilly's triple-g agonist scores another win in two Phase III trials

Eli Lilly reported positive Phase III trial results for its triple-g agonist targeting GLP-1, GIP, and glucagon receptors. If approved, it would be the company's fifth glucagon-based drug on the market.

July 23, 2026

2 min read

Source: Clinical Trials Arena

Eli Lilly (NYSE: LLY) announced the success of its triple-g agonist (GLP-1/GIP/Glucagon receptor agonist) in two Phase III clinical trials, as reported by Clinical Trials Arena. This achievement paves the way for regulatory approval, potentially adding a fifth glucagon-based drug to Lilly's portfolio.

Trial Details

Specific data from the two Phase III trials have not been disclosed yet. However, success at this stage strongly indicates efficacy and safety. Lilly is expected to submit a regulatory application soon.

Context

Lilly already markets four glucagon-based drugs, including Mounjaro (tirzepatide), which targets GLP-1 and GIP. The new triple-g agonist adds glucagon receptor activation, which may offer additional benefits for weight loss and glycemic control.

What This Means for Investors

This success strengthens Lilly's pipeline in the rapidly growing obesity and diabetes market. Approval could significantly boost revenue. However, competition from Novo Nordisk and others remains a factor to watch.

Frequently Asked Questions

It is a drug that activates three hormone receptors: GLP-1, GIP, and glucagon, aiding weight loss and blood sugar control.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.